RyboDyn

RyboDyn is a biotechnology company developing first-in-class immunotherapies targeting the dark genome. They utilize RyboCypher, a proprietary RNA sequencing technology, to identify and validate previously unknown proteins for use in novel cancer therapies. This approach offers a unique 'targets-to-assets' strategy for therapeutic development.


Buy Funded Startups lists

Funding Round: Pre-Seed

Funding Amount: $4M

Date: 09-Jan-2025

Investors: Genedant Capital, SeaX Ventures, SOSV, Swell VC

Markets: Biotechnology, Cancer Immunotherapy, Medical, Pharmaceutical, Therapeutics, Drug Discovery, HealthTech

HQ: San Diego, California, United States

Founded: 2022

Website: https://www.rybodyn.com

LinkedIn: https://www.linkedin.com/company/rybodyn

Twitter:

Instagram:

Facebook:

Crunchbase: https://www.crunchbase.com/organization/rybodyn

Pitchbook: https://pitchbook.com/profiles/company/498129-58


Leave a Comment